Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

High Prevalence of Superficial Metastases Supports Percutaneous Ultrasound-Guided Biopsy for Diagnosis and Molecular Profiling of Advanced Lung Cancer: Results from a Prospective Cohort.

Cancers·2026

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

JAMA oncology·2026

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

The Lancet. Oncology·2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

The Lancet. Oncology·2026

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

The Lancet. Oncology·2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

The Lancet. Oncology·2026

Clinical impact and therapeutic potential of tertiary lymphoid structures in melanoma.

Frontiers in immunology·2026

Gastric histiocytic sarcoma: a case report and literature review.

Frontiers in surgery·2026

Screening Potential Diagnostic Biomarkers of Lung Adenocarcinoma Related to Immune Infiltration Based on Single-Cell Proteomic Integration Analysis.

Canadian respiratory journal·2026

Tetanus after trauma despite post-exposure prophylaxis with human tetanus immunoglobulin: A case report.

Chinese journal of traumatology = Zhonghua chuang shang za zhi·2026

Multiscale modeling uncovers macrophage infiltration and TNF-α signaling networks for targeting in inflammatory breast cancer tumor emboli.

Breast (Edinburgh, Scotland)·2026

The Diagnostic Performance of Afirma Genomic Sequencing Classifier in Black and Hispanic Patients With Indeterminate Thyroid Nodules.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026

Related Experiment Videos

Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply

Related Concept Videos

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

High Prevalence of Superficial Metastases Supports Percutaneous Ultrasound-Guided Biopsy for Diagnosis and Molecular Profiling of Advanced Lung Cancer: Results from a Prospective Cohort.

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

Clinical impact and therapeutic potential of tertiary lymphoid structures in melanoma.

Gastric histiocytic sarcoma: a case report and literature review.

Screening Potential Diagnostic Biomarkers of Lung Adenocarcinoma Related to Immune Infiltration Based on Single-Cell Proteomic Integration Analysis.

Tetanus after trauma despite post-exposure prophylaxis with human tetanus immunoglobulin: A case report.

Multiscale modeling uncovers macrophage infiltration and TNF-α signaling networks for targeting in inflammatory breast cancer tumor emboli.

The Diagnostic Performance of Afirma Genomic Sequencing Classifier in Black and Hispanic Patients With Indeterminate Thyroid Nodules.

Related Experiment Videos

Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply

Related Concept Videos

Related Articles